Skip to main content




Psycheceutical Bioscience Inc. (OTCPK: BWVI) is a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments. Powered by a team of FDA drug development veterans, leading mental health scientists, and a network of international partners, Psycheceutical is on a mission to develop precision dosing technologies and more effective tools to provide the safe and effective delivery of psychedelic pharmaceutical medicines.

Our next-generation patented delivery technologies, via systemic and non-systemic routes of administration, are expected to allow psychedelics to be administered without unwanted side effects and toxicity, providing direct and profound benefits to those suffering from mental health disorders.


2 Patented Drug Delivery Technologies

designed to increase the safety and efficacy of psychedelic therapeutics while eliminating hallucinations and side effects.

2 Active Clinical Research Programs

NeuroDirect™ ketamine topical for PTSD — clinical trials Q2 2023.

Second drug for the treatment of addiction in pre-clinical stage.

An Experienced, Visionary Team

consisting of medical specialists, biotechnology scientists, FDA regulatory advisors, psychedelic industry insiders, and business development experts.


04/13/2023 in Press Releases

Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review

MIAMI — April 13, 2023 —Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments,…
Read More
03/29/2023 in Press Releases

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab

Doblin commented on the potential of the company’s NeuroDirect™ ketamine topical cream to help those suffering from PTSD...
Read More
03/21/2023 in Press Releases

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD

A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical cream Patients indicated their thought processes…
Read More


Latest Events

Upcoming Events



Investors are invited to learn more about Psycheceutical, and stay up to date on the latest news, events, and regulatory updates by contacting our team via the accompanying contact form.